Aerie Pharma initiates phase 2 clinical trial of AR-1105 (dexamethasone intravitreal)
Aerie Pharmaceuticals announced the commencement of patient dosing in a Phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion. This Phase 2 study (AR1105-CS201) will enroll up to 45 patients. March 18, 2019